Animal models of Alzheimer's disease and evaluation of anti-dementia drugs

Kiyofumi Yamada, Toshitaka Nabeshima

Research output: Contribution to journalReview article

135 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common cause of progressive decline of cognitive function in aged humans, and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. Some, but not all, of the neuropathological alterations and cognitive impairment in AD can be reproduced genetically and pharmacologically in animals. It should be possible to discover novel drugs that slow the progress or alleviate the clinical symptoms of AD by using these animal models. We review the recent progress in the development of animal models of AD and discuss how to use these model animals to evaluate novel anti-dementia drugs.

Original languageEnglish
Pages (from-to)93-113
Number of pages21
JournalPharmacology and Therapeutics
Volume88
Issue number2
DOIs
Publication statusPublished - 01-01-2000
Externally publishedYes

Fingerprint

Dementia
Alzheimer Disease
Animal Models
Pharmaceutical Preparations
Neurofibrillary Tangles
Amyloid Plaques
Cognition

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{661da71f30bd428e94fdfa219562d169,
title = "Animal models of Alzheimer's disease and evaluation of anti-dementia drugs",
abstract = "Alzheimer's disease (AD) is the most common cause of progressive decline of cognitive function in aged humans, and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. Some, but not all, of the neuropathological alterations and cognitive impairment in AD can be reproduced genetically and pharmacologically in animals. It should be possible to discover novel drugs that slow the progress or alleviate the clinical symptoms of AD by using these animal models. We review the recent progress in the development of animal models of AD and discuss how to use these model animals to evaluate novel anti-dementia drugs.",
author = "Kiyofumi Yamada and Toshitaka Nabeshima",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0163-7258(00)00081-4",
language = "English",
volume = "88",
pages = "93--113",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "2",

}

Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. / Yamada, Kiyofumi; Nabeshima, Toshitaka.

In: Pharmacology and Therapeutics, Vol. 88, No. 2, 01.01.2000, p. 93-113.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Animal models of Alzheimer's disease and evaluation of anti-dementia drugs

AU - Yamada, Kiyofumi

AU - Nabeshima, Toshitaka

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Alzheimer's disease (AD) is the most common cause of progressive decline of cognitive function in aged humans, and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. Some, but not all, of the neuropathological alterations and cognitive impairment in AD can be reproduced genetically and pharmacologically in animals. It should be possible to discover novel drugs that slow the progress or alleviate the clinical symptoms of AD by using these animal models. We review the recent progress in the development of animal models of AD and discuss how to use these model animals to evaluate novel anti-dementia drugs.

AB - Alzheimer's disease (AD) is the most common cause of progressive decline of cognitive function in aged humans, and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. Some, but not all, of the neuropathological alterations and cognitive impairment in AD can be reproduced genetically and pharmacologically in animals. It should be possible to discover novel drugs that slow the progress or alleviate the clinical symptoms of AD by using these animal models. We review the recent progress in the development of animal models of AD and discuss how to use these model animals to evaluate novel anti-dementia drugs.

UR - http://www.scopus.com/inward/record.url?scp=0034524088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034524088&partnerID=8YFLogxK

U2 - 10.1016/S0163-7258(00)00081-4

DO - 10.1016/S0163-7258(00)00081-4

M3 - Review article

VL - 88

SP - 93

EP - 113

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 2

ER -